Special Issue

Multidrug Resistance in Bacteria and New Therapeutic Options

Message from the Guest Editors

Antimicrobial resistance presents a critical threat to public health and a great challenge to clinicians treating patients in intensive care units. Clinicians often do not have any other therapeutic option, and have to rely on antibiotic combinations in order to treat the patient. In the last few years, new antibiotics have been licenced for the treatment of infections due to CRE, CRAB and CRPA, including ceftolozan/tazobactam (CTA) ceftazidime/avibactam (CZA),

imipenem/cilastatin/relebactam (IMR) and cefiderocol, as well as eravacycline, which is efficient against MRSA and VRE. The majority of these antibiotics exert good activity against KPC- and OXA-48-producing Enterobacterales and CRPA, but with the exception of cefiderocol, do not exhibit any activity against metalobeta-lactamase-producing organisms or CRAB. Thus, the scope of this Special Issue is mostly focused on the in vitro and in vivo activity of the novel compounds for the treatment of infections associated with CRE, CRPA and CRAB.

Guest Editors

Dr. Gordana Maravić Vlahoviček

Department of Biochemistry and Molecular Biology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia

Dr. Branka Bedenić

School of Medicine, University of Zagreb, Šalata ul. 2, 10000 Zagreb, Croatia

Deadline for manuscript submissions

closed (20 May 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/155871

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

